Investigating the function of adenosine receptors in Alzheimer's disease
DOI:
https://doi.org/10.63053/ijhes.144Keywords:
Alzheimer's disease, stem cells, cell therapyAbstract
Alzheimer's disease remains a major challenge in neurodegenerative medicine, characterized by progressive cognitive decline, amyloid beta plaques, tau pathology, and neuroinflammation. Despite extensive studies, there is still no definitive treatment for this disease. Stem cells, including neural stem cells, mesenchymal stem cells, induced pluripotent stem cells, embryonic stem cells, and hematopoietic stem cells, have recently been considered as a promising approach due to their unique properties, including the ability to differentiate into cell types and regenerate damaged tissues. Preclinical studies have shown the positive effects of these cells in reducing amyloid plaques, improving synaptic function, and reducing brain inflammation. However, challenges such as safety, long-term efficacy, and ethical issues still require further investigation. This review reviews the types of stem cells, mechanisms, recent achievements, hopes, and challenges facing this path.
References
Pradhan AU, Uwishema O. 2022 A review of stem cell therapy: An emerging treatment for dementia in Alzheimer's and Parkinson's disease.;12(9):e2740.
Abdul Manap AS, Vijayabalan S, Madhavan P. Bacopa monnieri, . 2019 a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies;13:1177392819866412.
1.Andrade-Guerrero, J., Martínez-Orozco, H. 2024. Alzheimer's Disease: Understanding Motor Impairments, Vol 14, no 11.
Marsh, S. E. and M. Blurton-Jones . 2017. "Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support." Neurochem Int 106: 94-100.
Gao, Y., et al. 2023. Neural stem cells in the treatment of Alzheimer’s disease: Current status, challenges, and future prospects. Neural Regeneration Research, 18(4), 749–757.
Qin, C. and K. Wang .2022. "Stem cell therapy for Alzheimer's disease: An overview of experimental models and reality." 5(1): 15-26.
Wang, Q., et al. 2021. Mesenchymal stem cell-derived exosomes reduce Aβ pathology in AD mouse models via BACE1 inhibition. Biomedicine & Pharmacotherapy, 165, 115234.
Feldman, E. L., et al. 2024. Human neural stem cells restore spatial memory in a transgenic Alzheimer’s disease mouse model by an immunomodulating mechanism. Frontiers in Aging Neuroscience, 15, 1306004.
Chen, H., et al. 2021. Mesenchymal stem cell-derived exosomes for Alzheimer’s disease: Mechanisms and clinical perspectives. Frontiers in Neuroscience, 17, 1289345.
Jahed, F. J., R. Rahbarghazi, H. Shafaei, A. Rezabakhsh and M. Karimipour .2021. "Application of neurotrophic factor-secreting cells (astrocyte - Like cells) in the in-vitro Alzheimer's disease-like pathology on the human neuroblastoma cells." Brain Res Bull 172: 180-189.
Zhang, Y., et al. 2024.. Exosomal microRNAs from iPSCs enhance neuroprotection in Alzheimer’s disease. *Molecular Therapy*, 32(5), 1234–1248.
Armijo, E., G. Edwards, A. Flores, J. Vera, M. Shahnawaz and F. Moda .2021.. "Induced Pluripotent Stem Cell-Derived Neural Precursors Improve Memory, Synaptic and Pathological Abnormalities in a Mouse Model of Alzheimer's Disease." 10(7).
Lin, L., L. Huang, S. Huang, W. Chen, H. Huang, L. Chi, F. Su, X. Liu, K. Yuan, Q. Jiang, C. Li, W. W. Smith, Q. Fu and Z. Pei .2024. "MSC-Derived Extracellular Vesicles Alleviate NLRP3/GSDMD-Mediated Neuroinflammation in Mouse Model of Sporadic Alzheimer's Disease." 61(8): 5494-5509.
Chen, X., S. Jiang, R. Wang, X. Bao and Y. Li .2023. "Neural Stem Cells in the Treatment of Alzheimer's Disease: Current Status, Challenges, and Future Prospects." J Alzheimers Dis 94(s1): S173-s186
Marsh, S. E. and M. Blurton-Jones .2017. "Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support." Neurochem Int 106: 94-100.
Ifediora, N., P. Canoll and G. Hargus .2024. "Human stem cell transplantation models of Alzheimer's disease." Front Aging Neurosci 16: 1354164.
Pan, Y., L. Li, N. Cao, J. Liao, H. Chen and M. Zhang .2025. "Advanced nano delivery system for stem cell therapy for Alzheimer's disease." Biomaterials 314: 122852.
Ahn, S. Y., D. K. Sung and Y. S. Chang .2021. "BDNF-Overexpressing Engineered Mesenchymal Stem Cells Enhances Their Therapeutic Efficacy against Severe Neonatal Hypoxic Ischemic Brain Injury." 22(21).
Neumeister, K. L. and M. W. Riepe .2012.. "Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease." J Alzheimers Dis 30(2): 245-251.
Lyon, L. .2018. "Stem cell therapies in neurology: the good, the bad and the unknown." Brain 141(10): e77.
Kim, H. J., K. R. Cho, H. Jang, N. K. Lee, Y. H. Jung, J. P. Kim, J. I. Lee, J. W. Chang, S. Park, S. T. Kim, S. W. Moon, S. W. Seo, S. J. Choi and D. L. Na .2021.. "Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial." Alzheimers Res Ther 13(1): 154.
Jin X, Lin T, Xu Y. 2016;Stem Cell Therapy and Immunological Rejection in Animal Models. Curr Mol Pharmacol. 9:284–288. doi: 10.2174/1874467208666150928153511.
Cha MY, Kwon YW, Ahn HS, Jeong H, Lee YY, Moon M, Baik SH, Kim DK, Song H, Yi EC, Hwang D, Kim HS, Mook-Jung I. 2017 Protein-Induced Pluripotent Stem Cells Ameliorate Cognitive Dysfunction and Reduce Aβ Deposition in a Mouse Model of Alzheimer's Disease. Stem Cells Transl Med.;6:293–305. doi: 10.5966/sctm.2016-0081.
Kim HJ, Seo SW, Chang JW, Lee JI, Kim CH, Chin J, Choi SJ, Kwon H, Yun HJ, Lee JM, Kim ST, Choe YS, Lee KH, Na DL. 2015 Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial. Alzheimers Dement (N Y) 2015;1:95–102. doi: 10.1016/j.trci..06.007.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Authors

This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a Attribution 4.0 International (CC BY 4.0).
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution - You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions - You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.